Agenus (Formerly known as Antigenics Inc. - New York)

108 articles with Agenus (Formerly known as Antigenics Inc. - New York)

• Agenus Reports Second Quarter 2017 Financial Results And Provides Corporate Update

  8/3/2017

• Agenus To Report Second Quarter 2017 Financial Results On August 3, 2017; Conference Call To Follow

  7/27/2017

• Agenus To Report First Quarter 2017 Financial Results On May 4, 2017; Conference Call To Follow

  4/27/2017

• Agenus Release: Company Announces Collaboration With The NCI To Evaluate The Combination Of Pembrolizumab (Keytruda, Merck & Co.) With Prophage (Agenus Inc.) Autologous Vaccine

  1/17/2017

• Agenus To Report Third Quarter 2016 Financial Results On October 27, 2016; Conference Call To Follow

  10/20/2016

• Agenus To Present At The Rodman & Renshaw 18th Annual Global Investment Conference

  9/6/2016

• Agenus Appoints Jean-Marie Cuillerot, M.D. As Vice President And Global Head Of Clinical Development

  7/6/2016

• Agenus Announces Commencement Of Phase I/II Clinical Trial Of Anti-GITR Checkpoint Antibody INCAGN1876 In Patients With Solid Tumors

  6/22/2016

• Agenus Reports Fourth Quarter And Full Year 2015 Financial And Operational Results And Recent Highlights

  3/3/2016

• Agenus Bags Novel Antibodies to Immuno-oncology Target for $44 Million+

  7/20/2015

• Agenus To Present At The Cowen and Company 35th Annual Health Care Conference

  2/26/2015

• Agenus Reports Third Quarter 2014 Financial Results

  10/31/2014

• Agenus Reports Second Quarter 2014 Financial Results

  7/24/2014

• Massachusetts' Agenus Touts Positive Phase 2 Data From HerpV Study

  6/26/2014

• Agenus (Formerly known as Antigenics Inc. - New York) Completes Acquisition of 4-Antibody AG

  2/13/2014

• Agenus (Formerly known as Antigenics Inc. - New York)’ Prophage Vaccine For Glioma Hailed As A "Very Promising Therapy" In An Editorial Published In The Journal Neuro-Oncology

  1/21/2014

• Agenus (Formerly known as Antigenics Inc. - New York) To Present At OneMedForum San Francisco 2014

  1/9/2014

• Agenus (Formerly known as Antigenics Inc. - New York)' Brain Cancer Vaccine Program Named A "Top Project To Watch" By Elsevier Business Intelligence

  11/18/2013

• Agenus Reports Third Quarter 2013 Financial Results

  10/24/2013

• Agenus (Formerly known as Antigenics Inc. - Lexington, MA) Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed Patients

  9/17/2013